Anticancer Therapies – News and Features

Three genomic tests separately predict the likelihood that a patient's breast cancer will reoccur after surgery without additional treatment.

A specific gene mutation may be useful in predicting the level of aggression of thyroid cancer and help guide treatment options and follow-up care.

Enzyme’s important daily function has implications for understanding cancer and neurological diseases, say U-M researchers.

MRC clinical trials unit to implement Whatman FTA Elute in DNA collection and preparation kits to study genetic markers affecting prostate cancer treatments.

Three micro RNA genes appear to be key partners of protective gene p53; their loss is linked to common type of lung cancer.

According to Rice University researchers, nanotubes packing powerful alpha-emitters could target lone cancer cells.

Quark's siRNA compounds for acute hearing loss slated for IND filing by year- end 2007.

BSD Medical gains exclusive rights to Duke’s treatment system for primary breast cancer using hyperthermia therapy.

Genomic Health Inc researchers have chosen Tecan’s liquid handling workstations to automate the multi-gene expression assay that predicts recurrence of cancer.

Collaboration will enable analysis of critical drug target family in patient cancer biopsies and selection of appropriate therapy.